Douglas E Williams
CIK 1184847 · EVP & President, R&D · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BIIB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
20 WILLIAM STREET SUITE 145
WELLESLEY HILLS, MA 02481
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | — | $3.99 | — | $0 | 2 | 2026-06-12 |
| Climb Bio, Inc. (ELYM) Delisted | Director | — | $5.11 | — | $0 | 4 | 2026-06-08 |
| SANA | EVP & President, R&D | — | $1.77 | — | $0 | 3 | 2024-03-08 |
| Codiak BioSciences, Inc. (CDAK) Delisted | President & CEO | 7,655 | $0.06 | $436 | -$30.7K | 8 | 2023-03-30 |
| OVID | Director | 5,000 | $2.35 | $11.7K | $32.4K | 7 | 2021-05-18 |
| IRWD | Director | 87,800 | $4.71 | $413.5K | $0 | 5 | 2019-04-03 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | — | $8.16 | — | $0 | 4 | 2016-06-03 |
| BIIB | EVP Research & Development | 11,817 | $247.78 | $2.93M | -$3.73M | 16 | 2015-06-22 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Director | 19,961 | — | — | $0 | 8 | 2013-06-14 |
| ZYMOGENETICS INC (ZGEN) Delisted | Chief Executive Officer | 0 | $12.01 | $0 | $47.0K | 12 | 2010-10-12 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | 4,500 | — | — | $4.7K | 4 | 2008-05-30 |
Recent Filings · Page 3 of 8
78 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-08-01 | OVID | Grant (A) | — | $0 | EDGAR |
| 2019-06-10 | OVID | Grant (A) | — | $0 | EDGAR |
| 2019-04-03 | IRWD | Disp (D) | −4,056 | $0 | EDGAR |
| 2018-08-16 | OVID | Buy (P) | +5,000 | $32.4K | EDGAR |
| 2018-06-08 | OVID | Grant (A) | — | $0 | EDGAR |
| 2018-06-04 | IRWD | Grant (A) | +16,223 | $0 | EDGAR |
| 2017-06-02 | IRWD | Grant (A) | +15,625 | $0 | EDGAR |
| 2016-06-03 | IRWD | Grant (A) | +23,674 | $0 | EDGAR |
| 2016-06-03 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-26 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).